Search Results - "Muniesa, B Hernández"

1ISG-010 Pharmacy staff satisfaction and opinion of new website application for outpatient care by Merino, A, Herrero Muñoz, N, Fernández Román, AB, Hernández Muniesa, B, Pou Alonso, A, Ontañón Nasarre, A, Pedreira Bouzas, J, Canalejo Fuentes, MJ, García Gil, M

“…Background and ImportanceUp until March 2022, medical prescription orders and next appointments were printed on paper for pharmaceutical validation and…”
Get full text

4CPS-090 Health outcomes using direct-acting antiviral drugs for the treatment of patients with hepatitis C virus and F0–F1 liver fibrosis stage by Martín López, M, Hernández Muniesa, B, Ontañón Nasarre, A, Pou Alonso, A, Herrero Muñoz, N, García Gil, M

“…BackgroundIn clinical trials, direct-acting antiviral (DAA) drugs stop hepatitis C virus (HCV) proliferation with efficacy rates near 100% in F0–F1…”
Get full text

4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017 by Muñoz, N Herrero, Rosado, A Andrés, Muniesa, B Hernández, Lázaro, C Bravo, Román, AB Fernández, Alonso, A Pou, Nasarre, A Ontañón, Gutiérrez, MDM García, López, C Mayo, Gil, M García

“…BackgroundAdalimumab is a monoclonal antibody indicated in immunomediate inflammatory diseases for subcutaneous administration by two different devices:…”
Get full text

Prevention of the refeeding syndrome by Martínez Núñez, Maria E, Hernández Muniesa, B

“…The refeeding syndrome can be defined as the metabolic alterations developed by the rapid nutrition repletion (oral, enteral as well as parenteral feeding) of…”
Get full text

Prevención del Síndrome de Realimentación by Martínez Núñez, Mª E., Hernández Muniesa, B.

“…El Síndrome de Realimentación puede definirse como el conjunto de alteraciones metabólicas desencadenadas tras la rápida reintroducción del soporte nutricional…”
Get full text

4CPS-045 Healthcare evaluation of hospital pharmacy services by patients with immune-mediated inflammatory diseases: a multicentre study by Calvo García, A, Escudero Vilaplana, V, Ramirez Herraiz, E, Hernandez Muniesa, B, Pacheco Garcia-Valdecasas, M Fernández, Romero Jiménez, R, Chamorro De Vega, E, Herrero Muñoz, N, Ubeda Ruiz, B, Morell Baladron, A

“…Background and importanceImmune-mediated inflammatory diseases (IMIDs) are a group of disabling chronic diseases.Aim and objectivesTo assess the satisfaction…”
Get full text

Prevención del Síndrome de Realimentación Prevention of the refeeding syndrome by Mª E. Martínez Núñez, B. Hernández Muniesa

“…El Síndrome de Realimentación puede definirse como el conjunto de alteraciones metabólicas desencadenadas tras la rápida reintroducción del soporte nutricional…”
Get full text

Retrospective analysis of the carboplatin dosage and relationship with toxicity in cancer patients by García Palomo, M, Castellanos Clemente, Y, Díez Fernández, R, Martínez Sesmero, J M, Iglesias Bolaños, A M, Hernández Muniesa, B

“…To analyse carboplatin dosage in cancer patients in order to establish whether they are over- or underdosed in comparison to the theoretical dose calculations…”
Get full text

Eficacia de maraviroc en los ensayos clínicos de desarrollo de la molécula by Moreno, Santiago, Hernández, Beatriz, Gutiérrez, Carolina, Delsol, Enrique

“…Maraviroc ha sido el primer antagonista de los correceptores en ser aprobado para su uso en pacientes infectados por el VIH. En el ensayo en fase II, en el que…”
Get full text

Análisis retrospectivo de la dosificación de carboplatino y relación con su toxicidad en pacientes oncológicos by García Palomo, M., Castellanos Clemente, Y., Díez Fernández, R., Martínez Sesmero, J.M., Iglesias Bolaños, A.M., Hernández Muniesa, B.

“…Realizar un análisis de la dosificación de carboplati-no en pacientes oncológicos para conocer si están sobre-o infra-dosificados con respecto a la dosis…”
Get full text